Nuwellis Posts Double-Digit Revenue Growth and Margin Expansion in Q2 2026
Event summary
- Nuwellis reported $2.0 million in net sales for Q2 2026, a 14% year-over-year increase, with U.S. revenue up 17%.
- Gross margin improved to 76% from 56% in the prior-year quarter due to pricing adjustments and contract manufacturing.
- The company sold nine consoles in Q2 2026, expanding its installed base for future circuit utilization.
- Nuwellis raised $12.7 million in gross proceeds through June and July financings, extending cash runway into Q2 2027.
The big picture
Nuwellis' Q2 2026 results highlight its strategic focus on expanding its cardiorenal platform, particularly in pediatrics and critical care. The company's ability to improve margins while increasing revenue suggests a potential shift in market positioning, though sustained growth will depend on successful execution of its commercial and regulatory strategies.
What we're watching
- Commercial Expansion
- How Nuwellis will leverage its expanded installed base to drive recurring circuit revenue growth.
- Regulatory Progress
- Whether the proposed Aquadex label expansion for patients weighing 5 kg or more will gain FDA approval.
- Operational Efficiency
- The pace at which Nuwellis can sustain its improved gross margin amid planned investments in commercial and product development.